# GI Dysmotility Symptoms Are Not Associated with Increased L-Dopa Requirements in Parkinson's Disease Patients



PRESENTER:

Jocelyn Chang

#### INTRODUCTION

dopa pharmacokinetics.

Gastrointestinal (GI) motility disorders like gastroparesis or small bowel bacterial overgrowth are **thought to impair efficacy of L-dopa**, absorbed in the proximal small intestine leading to—> motor fluctuations among Parkinson's Disease (PD) patients that prompt dosage increases.

Symptoms of dysmotility are frequently reported but results are mixed concerning their effect on L-

We compare L-dopa equivalent daily dose (LEDD) and motor function among patient with 5 upper GI symptoms to study the possible relationship.


### **METHODS**


We collected data from 200 PD patients evaluated by outpatient neurology at Mass General Brigham Healthcare between 2018-2019.

History of five upper GI symptoms, Unified PD Rating Scale (UDPRS) part III motor exam scores off medication, & LEDD were extracted from medical records:

- 1. Dysphagia
- 2. Nausea
- 3. Vomiting
- 4. Epigastric pain
- 5. Bloating

Differences between LEDD and UDPRS motor scores among patients with and without a history of each of the 5 GI symptoms were calculated via Student t-tests.





## In Parkinson's, GI Dysmotility may

NOT be directly related to poor

### L-Dopa absorption

despite being a common reason PD patients are referred to GI.

### **RESULTS**

GI Symptom	LEDD, mg (SD)	P value	UDPRS III (SD)	P value
Nausea	-187 (86)	0.03	1 (2)	0.633
Vomiting	11 (95)	0.91	-2 (2)	0.343
Dysphagia	230 (84)	0.007	5 (2)	0.036
Epigastric pain	101 (104)	0.33	0 (3)	0.881
Bloating	62 (99)	0.533	1 (2)	0.764

### DISCUSSION

Except dysphagia, GI dysmotility symptoms are NOT associated with increased LEDD or motor severity.

GI dysmotility may not be directly related to poor L-dopa absorption.

While dysphagia was linked with higher LEDD, this may have stemmed from higher UDPRS scores in this population.

Interestingly, those with nausea required lower LEDD despite comparable motor severity. Nausea, a frequent symptom of delayed intestinal transit, may extend absorption time leading to better motor outcomes on less L-dopa. However, further studies are needed to discern any underlying mechanism.

Clinical management of dysmotility may not reduce

motor fluctuations and the need for increased L-dopa as previously presumed.

Jocelyn Chang, BS<sup>1</sup>; Sanjay Gadi, MD<sup>2,3</sup>; Braden Kuo, MD<sup>3,4</sup>; Trisha Pasricha, MD, MPH<sup>3,4</sup>

<sup>1</sup>Tufts School of Medicine, Boston MA; <sup>2</sup>Duke University Department of Medicine, Durham NC; <sup>3</sup>Harvard Medical School, Boston MA; <sup>4</sup>Center for Neurointestinal Health, Division of Gastroenterology, Massachusetts General Hospital, Boston MA





